Table 5 Five-year survival and five-year all-cause mortality rate ratio (MRR) by level of comorbidity according to the FIGO-stages and adjusted for age and calendar time.
From: The impact of comorbidity and stage on ovarian cancer mortality: A nationwide Danish cohort study
| Â | Charlson Comorbidity score | ||
|---|---|---|---|
|  | 0 | 1–2 | 3+ |
Localized tumour/FIGO-stage I | Â | Â | Â |
   Survival in % | 79 (76–82) | 65 (57–72) | 50 (32–65) |
   Crude MRR | 1 (ref.) | 1.8 (1.4–2.5) | 3.2 (2.0–5.3) |
   Adj. MRR | 1 (ref.) | 1.6 (1.2–2.1) | 2.3 (1.4–3.8) |
Regional spread/FIGO-stage II, III | Â | Â | Â |
   Survival in % | 33 (31–36) | 21 (17–25) | 12 (7–18) |
   Crude MRR | 4.5 (3.8–5.4) | 6.7 (5.6–8.1) | 10.1 (8.0–12.7) |
   Adj. MRR | 4.4 (3.7–5.2) | 5.7 (4.7–6.9) | 8.6 (6.8–10.9) |
Distant metastases/FIGO-stage IV | Â | Â | Â |
   Survival in % | 12 (10–14) | 8 (5–12) | 2 (0.4–6) |
   Crude MRR | 9.7 (8.1–11.5) | 12.4 (10.2–15.0) | 15.9 (12.6–20.0) |
   Adj. MRR | 8.9 (7.5–10.6) | 9.7 (8.0–11.8) | 12.1 (9.6–15.4) |
Unspecified | Â | Â | Â |
   Survival in % | 36 (29–43) | 17 (10–26) | 14 (5–29) |
   Crude MRR | 5.1 (4.0–6.5) | 9.8 (7.5–12.8) | 11.8 (8.0–17.5) |
   Adj. MRR | 4.6 (3.6–5.8) | 6.8 (5.2–8.9) | 8.0 (5.4–12.0) |